9999999997-17-005839.txt : 20170501 9999999997-17-005839.hdr.sgml : 20170501 20170501113509 ACCESSION NUMBER: 9999999997-17-005839 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170501 DATE AS OF CHANGE: 20170501 20170501 20170501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verona Pharma plc CENTRAL INDEX KEY: 0001657312 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1933 Act SEC FILE NUMBER: 333-217124 FILM NUMBER: 17799245 BUSINESS ADDRESS: STREET 1: 3 MORE LONDON RIVERSIDE CITY: LONDON STATE: X0 ZIP: SE1 2RE BUSINESS PHONE: 011-44-0-2032834200 MAIL ADDRESS: STREET 1: 3 MORE LONDON RIVERSIDE CITY: LONDON STATE: X0 ZIP: SE1 2RE CT ORDER 1 filename1.pdf begin 644 filename1.pdf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end